An interim analysis of a Phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis

This randomized, double-blind, placebo-controlled, Phase 2 crossover trial examined the use of extended-release oral nalbuphine for the treatment of chronic cough in 26 patients with idiopathic pulmonary fibrosis. The primary endpoint was percent change from baseline in hourly daytime cough frequency, which was measured using the Vitalograph VitaloJAK cough monitor.